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blind pilot-study to evaluate safety and efficacy of 
the non-absorbable Optilene® Mesh Elastic versus 
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Abstract
Background: Randomised controlled trials with a long term follow-up (3 to 10 years) have demonstrated that mesh 
repair is superior to suture closure of incisional hernia with lower recurrence rates (5 to 20% versus 20 to 63%). Yet, the 
ideal size and material of the mesh are not defined. So far, there are few prospective studies that evaluate the influence 
of the mesh texture on patient's satisfaction, recurrence and complication rate. The aim of this study is to evaluate, if a 
non-absorbable mesh (Optilene® Mesh Elastic) will result in better health outcomes compared to a partly absorbable 
mesh (Ultrapro® Mesh).
Methods/Design: In this prospective, randomised, double blind study, eighty patients with incisional hernia after a 
midline laparotomy will be included. Primary objective of this study is to investigate differences in the physical 
functioning score from the SF-36 questionnaire 21 days after mesh insertion. Secondary objectives include the 
evaluation of the patients' daily activity, pain, wound complication and other surgical complications (hematomas, 
seromas), and safety within six months after intervention.
Discussion: This study investigates mainly from the patient perspective differences between meshes for treatment of 
incisional hernias. Whether partly absorbable meshes improve quality of life better than non-absorbable meshes is 
unclear and therefore, this trial will generate further evidence for a better treatment of patients.
Trial registration: NCT00646334
Background
Rationale
70.000 incisional hernia repairs were performed in Ger-
many in 2006 [1]. Incisional hernias can cause serious
complications such as incarceration or strangulation,
resulting in substantial costs for further treatment (~ 128
Million €). Optimal treatment has not yet been defined
[2,3].
Currently, the surgeon usually implants a mesh to rein-
force the abdominal wall. The use of a mesh prosthesis
for incisional hernia repair results in a lower recurrence
rate than suture repair [4-11]. Creating a tension free
repair with a mesh reduces the recurrence rate to 5-10%.
Studies performed by Israelsson et al. in 2006 [12] and
Kingsnorth et al. in 2004 [13] showed that the sublay
technique seems to result in a lower recurrence rate (3-
7%) compared to the onlay technique (12-19%). In order
to achieve a sufficient reinforcement of the abdominal
wall, the mesh should overlap the defect more than 5 cm
in all directions [13-15]. Several meshes are available
which differ in material, textile structure, pore size,
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weight, elasticity, tissue reaction, biocompatibility, and
absorption [16-22]. Patients react differently to the mesh
and the materials cause different complications such as
seromas, chronic pain, and infections [14,15,19,23,24].
Purpose
The aim of this study is to evaluate the safety and efficacy
of the Optilene® Mesh Elastic manufactured by B|Braun
Aesculap compared to, the Ultrapro®  Mesh by John-
son&Johnson. Surgeons currently use both meshes to
repair incisional hernias [25-27]. The two meshes have
large pores based on polypropylene. Optilene® Mesh Elas-
tic is made of pure polypropylene and is not absorbable.
Ultrapro® is a partly absorbable mesh (polypropylene plus
polyglecaprone, table 1).
Methods/Design
Study objectives
The primary objective of the study is to compare the
physical functioning score from the SF-36 questionnaire
21 days after insertion of either an Optilene® Mesh Elastic
or an Ultrapro® Mesh. Secondary objectives include the
evaluation of the patients' daily activity, pain, wound
assessment determined on several occasions during the
observation time, the incidence of specific post-surgical
complications and safety.
Study design
The study is a prospective, randomised, patient and
observer blinded study. It is conducted in six centres in
Germany. In total eighty patients with incisional hernia
meeting the specific inclusion criteria will be randomised
and followed for six months thereafter (table 2 and figure
1). Patients who prematurely terminate participation in
the study will not be replaced.
Study population
Female or male patients over 18 years old undergoing an
elective repair for a midline incisional hernia are eligible
for participation (table 3).
Ethics and informed consent
The commercial regulatory authority Hannover gave its
positive approval in February 2006. For the two centres in
Heidelberg the Ethics Committee of the University of
Heidelberg Medical School approved the final protocol
on the 8th Oktober 2007 and on 20th November 2007. A
central ethics approval was also obtain from the Interna-
tional Ethics Committee of Freiburg on the 4th May 2009.
Written informed consent will be obtained from all
patients participating in the trial. The study is conducted
in accordance with the principles of the Good Clinical
Practice (GCP) guidelines, the Declaration of Helsinki,
and the European Standard EN ISO 14155 Parts I and II
(2003), "Clinical Investigation of Medical Devices for
Human Subjects".
Randomisation and blinding
Patients will be randomised by opening sealed, opaque
envelopes containing the mesh to be implanted. The
sponsor will prepare envelopes with a balanced distribu-
tion of meshes, according to the randomisation plan. The
m e s h e s  w i l l  b e  a s s i g n e d  t o  p a t i e n t s  i n  e a c h  c e n t r e  i n
chronological order. Neither the patient nor the observer
will have access to the documents indicating mesh distri-
bution. The surgeon should not be the observer of out-
comes in this clinical trial. Therefore, at least two
different persons per centre are involved in this study,
one who performs the surgery and the other one con-
ducting the follow-up examinations. Together with the
meshes the study centres receive emergency envelopes
with the information of treatment allocation. The spon-
Table 1: Comparison of the two meshes
Characteristics Ultrapro Optilene Mesh Elastic
Material PP & PG (~ 1:1) PP
Filament Structure Monofil Monofil
Construction Knitted Knitted
Weight
after absorption of PG
65 g/m2
28 g/m2
48 g/m2
Thickness 0,59 mm 0,55 mm
Pore Size 1.9 - 2.2 mm
(min.- max.)
2.9 - 3.2 mm
(min.-max.)
Absorption partly absorbable non-absorbable
Suture pull out test, lengthwise 33 N 33 N
Suture pull out test, crosswise 31 N 44 N
PP: Polypropylene, PG Polyglecaprone, N: NewtonSeiler et al. BMC Surgery 2010, 10:21
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Table 2: Tabular overview of the visits
Visit 1
Pre-
Surgery1
Visit 2
Surgery
0 Day 
Visit 3 
Release
Visit 4
Clinic 
21 Days 
Visit 5
Telephone
4 Months
Visit 6
Clinic
6 Months2
Patient information X
Informed Consent X
Demographics incl. employment
status and home activities
X
Body weight X X
Inclusion/Exclusion X
Medical history incl. history hernia X
Determination of potential risk factors X
Clinical examination X X
Concomitant medication X X3 XX X X
General health status X X X
SF-36 X X X
Daily activity questionnaire X X X
Intra-operative details X
Adverse Events X X X X X
Wound assessment X X X
Seroma formation
(sonography if indicated)
XX X
Pain score X X X X
Study termination X
1) to be performed within 6 weeks before visit 2
2) or prematurely
3) concomitant medication except medication routinely given during a surgery and anaesthetic drugSeiler et al. BMC Surgery 2010, 10:21
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sor has to be contacted before breaking the code for a
given patient. In case of opening the envelope, time, date,
name of the person opening and the reason for opening
the envelope are to be documented on that envelope and
in the corresponding CRF.
Intervention
In order to minimise bias and to assure parity in treat-
ment for all patients, the following standardised proce-
dures were implemented.
The operation is initiated with a vertical median inci-
sion. After classification of the hernia according to
Schumpelick, a space is created between both posterior
sheaths and the rectus muscle. The posterior fascia is
closed using a running monofilament non-absorbable
suture. The mesh is placed in sublay position between the
posterior rectus sheath and the rectus muscle with an
overlap of the defect of 5 cm in all directions (figure 2).
Whereby the largest elasticity of the mesh is in vertical
direction. The mesh is then fixed to the posterior fascia
using a single knot technique every 3 cm with monofila-
ment, non-absorbable suture material. The closure of the
midline anterior rectus sheath is conducted with a con-
tinuous running technique using monofilament, non-
absorbable sutures with a 4:1 ratio (suture length: incision
length). Two Redon drains are placed close to the mesh.
The skin is closed with tacks and an abdominal bandage
is applied.
Data collection and examinations
The investigator will collect data in a CRF about the
patient and perform six examinations (table 2). CRF are
paper-based and will be entered into a database by two
persons independently applying plausibility checks. Que-
ries raised during data base input will be clarified with
the investigators.
Questionnaires
The SF-36 Health Survey is a validated instrument to
measure health status and patients are requested to com-
plete the questionnaire before surgery, on day 21 after
intervention and six months postoperatively.
Documentation during and after surgery
During surgery, the investigator documents the size of
the incision, the device and the material used for fixation,
intra-operative complications, classification of the defect,
and the size of the overlap of the mesh. The observer will
Figure 2 Sublay technique for open incisional hernia repair.
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Figure 1 Flow-chart of the trial.
Population          Patients undergoing an elective incisional hernia repair
Screening                                       Inclusion / Exclusion criteria 
Eligible   Not eligible 
Informed Consent/ Enrolement                 
Preoperative Randomisation Preoperative Randomisation
Day of surgery Optilene Mesh Elastic / Ultrapro Mesh
Day of discharge                     
21 Days after surgery Clinic Primary endpoint 21 Days after surgery Clinic Primary endpoint
4 Months after surgery                   Telephone interview
6 Months after surgery      Clinic                               Secondary endpoint     
Table 3: Eligibility
Inclusion Criteria Exclusion Criteria
Patient is female or male and ≥ 18 years old Patient participates simultaneously in an investigational drug or 
medical device study
Female patients are incapable of pregnancy or
must be using adequate contraception and are
not in lactation
Patient has an acute incarcerated hernia
Patient had a previous mesh repair at the same site
Patient has only a vertical aponeurotic incision Enterotomy to be performed during hernia repair at Visit 2
Patient has an incisional hernia with a hernia size ≥ 3 cm Patient is on anti-coagulation therapy
Patient is capable to understand and to follow the instructions Patient is known or assessed to be non-compliant
Written informed consent is available Patient must not get any additional surgical treatment at the same 
time (e. g. cholecystectomy)
Patient had no mesh implantation at the same site during a 
previous operation
Patient is immune incompetent (e. g. chemotherapy)Seiler et al. BMC Surgery 2010, 10:21
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record wound assessment, daily activity and pain as sec-
ondary endpoints (table 2).
Safety aspects
The investigator has to document adverse events and
serious adverse events on the appropriate form of the
CRF which occur in the abdomen. Serious adverse events
occurring during the study or within two weeks after dis-
continuation have to be reported to the sponsor within 24
hours of becoming aware of the event. It is the responsi-
bility of the principal investigator at each centre to inform
the local ethics committee of SAEs occurring at the cen-
tre according to local requirements.
Sample size and statistical analysis
The primary efficacy endpoint is the change of SF 36 PCS
between baseline and average of SF 36 PCS 21 days after
intervention. The primary efficacy analysis will be con-
ducted in the intention-to-treat population and applies a
fixed effect linear model adjusting for age, BMI and SF 36
PCS before. Level of significance is set at 5% (two-sided).
Due to the lack of any empirical data for the primary
endpoint in the population under investigation, there is
substantial uncertainty with respect to overall rate and
treatment effect to be expected. As a consequence, the
assumptions to be made for sample size calculation are
highly uncertain and therefore, the study is performed as
a pilot randomised trial with 80 patients.
Secondary endpoints are level of function and daily
activity, seroma formation, wound assessment, neural-
gias, time to return to work and to normal activities, the
patient's rating of pain, analgesic consumption and other
SF-36 scores during 6 months after surgery. These data
will be analysed descriptively. No confirmatory statistical
testing will be done with regard to secondary endpoints.
Details of the analysis of secondary outcome parameters
will be documented before database lock in the analysis-
plan. The safety assessments, including adverse events
and serious adverse events, will be analysed descriptively.
Trial organization, coordination and registration
This study is initiated and sponsored by B|Braun Aescu-
lap. Aesculap AG conducts it in cooperation with the
CRO Dr. med. Lenhard&Partner GmbH. The CRO is
responsible for monitoring, biostatistics and database.
Aesculap AG is responsible for the project management.
The sponsor supplies the participating trial centres with
the meshes used in the trial. Aesculap AG is responsible
for the registration (Identifier Number NCT 00646334,
http://www.clinicaltrials.gov) and all trial related meet-
ings.
Monitoring
Data documentation and case report forms (CRF) will be
reviewed for accuracy and completeness during on-site
monitoring visits and at the sponsor's site. The first mon-
itoring visit after the study initiation will be made as soon
as the enrolment of patients has begun. On these visits,
the monitor will perform source data verification, i.e.
compare the data entered in the CRFs with the hospital
records. The trial centres may be visited either by repre-
sentatives of the sponsor or the local authorities to per-
form an audit.
Current status
The first investigator meeting was held on 21st December
2005 in Tuttlingen, Germany. The study protocol for this
trial was completed on 19th January 2006. In February
2006, following completion of contracts the first three
centres (Hannover, Aschaffenburg, Northeim) were initi-
ated, the first patient was recruited in July 2006. Due to
slow accrual of patients three other centres (University of
Heidelberg, University of Mannheim, Salem Hospital in
Heidelberg) were initiated in December 2007. It is
expected that the last patient will be randomised in
November 2009. The study is estimated to be completed
in June 2010.
Discussion
Incisional hernia is a common complication after abdom-
inal surgery with a reported incidence between 11 and 20
percent [6,8,10,28]. Such hernias can cause serious com-
plications such as strangulation or incarceration [2,3].
Many techniques are currently in use to repair incisional
hernias. Primary suture repair has been widely used, but
results in a high recurrence rate between 24% and 54%
[5,10,29,30]. With the development of new synthetic
materials the use of prosthetic meshes has gained popu-
larity in the treatment of incisional and ventral hernias
[31]. The mesh facilitates closure, minimizes tension on
the suture line, and assures high wound strength [32,33].
The use of prosthetic mesh is associated with a lower
incidence of hernia recurrence, ranging from 2 to 36 per-
cent [5,10,11]. A prospective, long-term, comparative
study showed that, for both small and large incisional
hernias, mesh repair was superior to suture repair in
regards to recurrence [8]. In addition the incidence and
intensity of abdominal pain were also lower after mesh
repair than after suture repair.
Several trials have been performed in order to find the
optimal mesh [19,24,34-37] and the ideal technique for
implantation [13,38]. The onlay and the sublay technique
are used in open mesh repair [12,13,38]. Both techniques
give good results but the sublay technique seems superior
in regard to complications and recurrence rate. The inlay
technique is nowadays rather rarely used [9,12,38]. The
size of the prosthesis is also important for the recurrence
rate of incisional hernias [24,39-41]. The mesh should
coverlap the defect more than 5 cm in all directions fromSeiler et al. BMC Surgery 2010, 10:21
http://www.biomedcentral.com/1471-2482/10/21
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the margin of the hernia, in order to achieve a sufficient
reinforcement of the abdominal wall [13-15,24,41].
The manifold available meshes differ from each other in
their material, in their textile structure and in their tissue
reaction and absorption. Evaluation of the different
meshes for incisional hernia repair is of special interest
because they are different in their biocompatibility and
complication rate. Pain, seroma and persisting infection
are known mesh-related complications [15]. Most studies
showed a high incidence of seroma formation after mesh
repair [5,8,10,42]. But with conservative treatment most
of these eventually resolve. The inflammatory activity of
the mesh mainly depends on the amount of material and
its textile structure [35,43,44]. In accordance, the major-
ity of these problems are associated with small pore-
sized, heavy-weight, meshes [15]. In some patients, an
excessive shrinkage of these meshes cause considerable
complaints and even require a mesh change [15]. To over-
come this problem, another form of mesh was introduced
the large pore-sized, light-weight mesh. They rarely cause
severe mesh-related problems, due to their reduced
amount of polymer [19,24]. With these materials, patients
report less pain, less mesh awareness and show less
symptoms such as a "stiff abdomen" [19,23,24].
Partly absorbable meshes have also been compared
with non-absorbable heavy-weight large pore-sized
meshes [19,24]. No difference in the incidence of wound
infections and the rate and the volume of seroma were
found [19,24]. But these studies did not analyse the role of
the absorbable and the non-absorbable part in causing
complications [19]. Currently most surgeons favour large
pore-sized, light-weight, elastic, monofilament polypro-
pylene meshes in the sublay position for reinforcement of
the abdominal wall [14,19,23].
There are only few prospective studies that evaluate the
influence of the mesh texture on patient's Quality of Life.
So far no randomised controlled trial, which evaluates if
the absorbable part of a mesh increases the rate of wound
infections, pain, patients discomfort, and other complica-
tions after mesh implantation has been published. It
remains unclear whether the application of partially
absorbable components might contribute to improve-
ment of the biocompatibility of polypropylene meshes
and whether such improvement would decrease the inci-
dence of wound infections or other complications. There-
fore, this study was designed, focusing on patient related
outcomes.
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